News | June 14, 2021
Sun Pharma’s US Specialty business to grow at 21% CAGR in 2 years
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company expects to see steady performance led by new launches and gradual normalization post the scale-up in vaccination
The company does not believe that the warning letter will have an impact on disruption of supplies or the existing revenues from operations of this facility
In an exclusive interview with Rahul Koul of Indian Chemical News, Priyanka Chigurupati, Executive Director, Granules Pharmaceuticals Inc. USA shared details about the company's performance, R&D initiatives, Capex plan, CSR, and future outlook. Excerpts of the interview:
The study was conducted in patients with mild to moderate COVID-19
The company is doubling its chemistry research capacity that should commission by Q2'FY22
Pegfilgrastim has estimated annual sales of USD 3.66 billion in the U.S. (IQVIA MAT December 2020).
The company reported total income of Rs.634.79 crores during the 12 months period ended March 31, 2021
Production line at Lonza’s site in Geleen will complement the existing production network and support the manufacture of up to an additional 300 million doses per year
The company has posted net profit of Rs.147.78 crores for the 12 months period ended March 31, 2021
The company reported total income of Rs.24774.63 crores during the 12 months period ended March 31, 2021
Subscribe To Our Newsletter & Stay Updated
